key: cord-1010063-5kl7nhop
authors: Ślizień, Zuzanna; Muchlado, Marta; Kubanek, Alicja; Biedunkiewicz, Bogdan; Renke, Marcin; Komorowska, Karolina; Dębska-Ślizień, Alicja; Tylicki, Leszek
title: Safety and tolerability of mRNA COVID-19 vaccines in kidney transplant recipients.
date: 2022-03-17
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2022.02.025
sha: 647c81d74373f8bb176646fa324d4c41e28b6023
doc_id: 1010063
cord_uid: 5kl7nhop

Introduction : COVID-19 mRNA vaccines have demonstrated excellent short-term safety in phase 3 trials. However, no kidney transplant recipients (KTR) were included. The aim of the study was to assess the safety and tolerability of COVID-19 mRNA vaccines in KTR. Materials and methods : A longitudinal controlled study was conducted in 300 KTR and 143 control patients (CRL) without chronic kidney disease who had received two-dose vaccinations with the mRNA vaccine. Solicited local and systemic reactogenicity, unsolicited adverse events (AE) were assessed with a standardized questionnaire. The toxicity grading scales were derived from the FDA guidelines. Results : KTR (62.7% men) with a median (IQR) age of 53 (41-63) and transplant vintage of 7.25 (3-13) years did not differ with respect to age and sex distribution from CRL. 100% CRL and 83.3% KTR were vaccinated with BNT162b2 (BionTech/Pfizer); 16.7% KTR received mRNA-1273 (Moderna) vaccine. Any local reactions were present in 84.7% (1st) and 65.3% (2nd) KTR vs. 67.1% and 60.1% CRL within seven days after the vaccination. Any systemic reactions were reported by 26.7% (1st) and 20.9% (2nd) KTR vs. 24.7 and 35.7% CRL. The most common systemic reactions in KTR were: fatigue, headache and myalgia. No serious AE were observed. Many systemic reactions were observed less frequently in KTR than CRL. Younger KTR (<54 years) reported any local and any systemic reactions significantly more frequently than older patients. Conclusions : mRNA COVID-19 vaccines are safe and well-tolerated by KTR. The results may resolve patients' doubts and reduce their vaccine hesitancy.

Kidney transplant recipients (KTR) are particularly vulnerable to infections including SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection. It is a result of the impaired immunity of patients with chronic kidney disease (CKD) and the need to take immunosuppressive drugs after kidney transplantation. KTR in the UK registry were infected less frequently than patients on the waiting lists, but their mortality rate was 2.5-times higher (10.2% vs.

25.8%) [1] . It was found that the COVID-19-related mortality among KTR ranged from 17.9% to 28%. The mortality in hospitalized KTR was 37.8%, 23% of them required kidney replacement therapy and 6.3% lost their allografts [2, 3] . Moreover, even 60% short-term mortality has been reported in the case of older KTR [1, 4] . In the absence of an effective COVID-19 treatment the only chance to improve prognosis is an effective . Many patients refuse vaccination because of the possibility of side-effects. This vaccine hesitancy, according to a survey performed on 1000 adult Poles, reaches 49.2% [6] . Patients are concerned over solicited local, systemic reactogenicity, and most of all unsolicited adverse events such as rare thrombotic events, anaphylaxis and ischemic stroke. mRNA vaccines against SARS-CoV-2 approved for use in the US and Europe were shown to have a favorable safety profile, and its reactogenicity was generally mild or moderate [7, 8] . However, pivotal studies were not performed in the population of KTR. The aim of the study was to assess the safety and tolerances of vaccinations with COVID-19 mRNA vaccines performed in KTR according to the manufacturer's protocol, and comparing the results in the general population that received the same vaccines. Awareness of the anticipated side-effects, their frequency and severity may resolve patients' doubts and reduce their vaccine hesitancy.

Retrospective and longitudinal analysis was conducted in the whole population of KTR from the Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk vaccinated with the first dose of intramuscular mRNA-Covid vaccine between the 8 th of March 2021 and the 24 th of March 2021. According to the rules of the national immunization program, and the manufacturer's recommendations, patients received the second dose after no more than 42 days. The control group, matched for age and gender, consisted of patients without CKD vaccinated in the University Centre of Maritime and Tropical Medicine in Gdynia with the same vaccines and doses.

Medical data of participants from both groups was taken from their medical history. In this report, safety data is reported for all patients who signed an informed consent form.

The primary end points of the study were solicited local and systemic reactogenicity, unsolicited adverse events (AE) reported by the participants of the study. The questionnaire used in registry studies of the mRNA vaccines (mRNA Comirnaty (Pfizer/BioNTech) and mRNA Spikevax (Moderna) was used to assess the adverse events [7, 8] . Solicited local (pain, redness, swelling), and systemic reactogenicity (fever, fatigue, headache, chills, vomiting, diarrhea, new/worsened muscle or joint pains) were graded in a 1-4 scale as we previously described [9] . Data was registered within the 7 days from the first and second dose of vaccination, and within 30 days of the second dose of vaccine, assessed with a standardized questionnaire during a telephone interview. The grading scales (the same as in the pivotal trial) used in this study were derived from the FDA Center for Biologics Evaluation and Research (CBER) guidelines on toxicity grading scales for healthy adult volunteers enrolled in preventive vaccine clinical trials [7, 8] . In secondary analyses we evaluated the vaccine safety in subgroups. We used the following strata: age (18-55 years vs. >55 years, the same as in the pivotal study), sex, diabetes, neoplastic disease, median BMI (<25.31 vs. >25.31), median Charlson Comorbidity Index (CCI) (<4 vs. >4) and the median time after kidney transplantation (<7.25 vs.

>7.25). The study is part of the 'COVID-19 in Nephrology' (COViNEPH) project registered in the ClinicalTrials.gov, identifier NCT04905862. The results were compared to the results published in the registry study and to the results of the control group.

We report descriptive results of the safety analyses, and the sample size was not determined on statistical hypothesis testing. Data was presented as a percentage for categorical variables, and as a median (interquartile range; IQR) for continuous variables. Chi-square or Fisher's exact test was used for categorical variables. Mann-Whitney U-tests or t-tests were used to compare continuous variables as appropriate. P < 0.05 was considered significant. (Table 1) .

Of the KTR 84.7% and 65.3% (p<0.001) of patients reported at least one local side-effect within 7 days after 1 st and 2 nd doses of the mRNA vaccination, respectively. Most of the adverse reactions were mild. Only 1 participant reported severe (grade 3) redness after the 1 st dose of the vaccine. The most frequently reported local adverse reaction was pain at the injection site (84.3% after 1 st dose and 64.3% after 2 nd dose). After the first dose of the vaccine control patients reported any local reaction less frequently than participants from the study group (lower pain reporting), but they reported swelling and redness significantly more often. After the 2 nd dose the groups did not differ in respect to any local adverse reaction. The grade of all local symptoms was also higher in KTR group (moderate and severe reactions were reported more often). However any local adverse events in KTR were reposted significantly less frequently after the second dose (p<0.001) Details are presented in 

Of the KTR 26.7% and 24.7% patients reported any solicited systemic adverse event after 1 st and 2 nd dose of the vaccination, respectively. Fatigue, headache and muscle pains were the most often reported symptoms. The vast majority of reported symptoms were mild. Grade 3 symptoms were reported by a few participants, and no grade 4 symptoms were reported. The participants from the control group reported any systemic reactions in 20.9% and 35.7% (p<0.05) after the 1 st and 2 nd doses, respectively.

After the 2 nd dose they reported any systemic events more often than KTR from the study group. Most adverse events in this group were mild, however participants reported grade 2 and 3 symptoms more often than patients after kidney transplantation. Details are presented in Figures 1 and 3 .

In univariable analyses any local adverse events were more frequent after the 1 st and 2 nd doses of vaccination in younger rather than in older patients ( We also checked the local and general reactogenicity of patients vaccinated with 2 types of mRNA vaccines (BNT162b2 mRNA and mRNA-1273). We showed no significant differences in local and overall reactogenicity in these two groups (see details in table 3).

No serious adverse events within 30 minutes of the vaccinations occurred in KTR and in the control group. No serious adverse events and clinical rejection or kidney graft failure episodes had occurred by the end of the follow-up in the 30 days after vaccination.

Since December 2020, many regulatory agencies (including the European and the American Societies for Transplantation) approved a two-dose regimen of the SARS-CoV-2 mRNA vaccines in solid organ transplant recipients (SOTR) [10] . The efficacy of SARS-CoV-2 vaccination in SOTR however is low, fewer than 50% of KTR responded after the second dose and also the immunity is rapidly waning [11] [12] [13] [14] [15] . There are reports that showed improved the antibody-mediated response to the administration of a third dose of mRNA vaccines which was recently recommended [15] [16] [17] [18] . A study of populations prioritized for early immunization found that around 50% of respondents were either not likely, or only somewhat likely, to receive a vaccine [19] . Concern for safety has been the main reason for fear and hesitancy to vaccinate against SARS-CoV-2. As there is a risk that SARS-CoV-2 may remain a persistent threat to the health and life of KTR, vaccination may stop the spread of new virus variants and limit the severe course of the disease, especially in immunocompromised individuals. Conducting studies demonstrating the safety and efficacy of vaccines not only in the general population but also in vulnerable populations is an essential tool for the widespread acceptance and adherence to repeated vaccination.

Overall, the reactogenicity profile in our study was in line with the results observed in clinical trials in the general population and KTR [20] [21] [22] . The most frequently reported local solicited adverse reaction was mild-to-moderate pain at the injection site, and the most often reported systemic reactions were fatigue, headache and muscle pains.

Any local solicited reactions were more frequent in KTR as compare to the controls due to more often noticed pain, although they reported swelling and redness significantly less often. The low incidence of swelling and redness in KTR was probably related to local anti-inflammatory effect of immunosuppressants. Any local reactions were more frequent in younger than in older patients. KTR Many systemic reactions were observed less frequently in KTR than in the control group. As was mentioned above also local solicited reactions (except local pain) occurred less frequently in KTR with respect to the age-and sex-matched control group and much less frequently than that reported in the pivotal studies [7, 8] . Comparing these results with our previous findings in chronic dialysis (CD) patients there were more local side reactions in KTR than CD patients after the first and second vaccination (84.7 vs. 59.8% after 1 st and 65.3 vs. 61.4% after 2 nd dose). Regarding systemic symptoms, there were more frequent in KTR as compare to CD after the 1 st dose (26.7 vs. 15.9%) and less frequent after 2 nd dose (20.9 vs., 29.4%) [9] . A higher percentage of adverse events in the KTR group may be associated with the lower age of our cohort as compared to CD patients (53 vs. 67 years old). It is in line with the observation that the younger patients reported any systemic and some local solicited adverse reactions more frequently than older patients. Additionally, the poorer reactivity of CD patients may be related to uremia-associated immunodeficiency, aging of the immune system and accelerated -inflammaging-, however it is less probable since KTR are also immunocompromised [23, 24] . Reactogenicity in our KTR was generally mild or moderate, reactions were transient and resolved in most participants by day three after vaccination, without sequelae. Similar to the control group and general population studies, younger patients and women were more likely to report adverse events than older subjects and men, respectively [22, 24] . We did not find significant differences in reactivity after vaccination with 2 types of mRNA vaccines despite the higher dose of mRNA in the mRNA-Our observational study has some limitations. The control group was not exactly matched as there were too few people with comorbidities such as diabetes, hypertension and neoplastic diseases. The influence of media interest on the excessive number of reports cannot be ruled out. In addition, patients receiving routine drugs in observational studies have a different level of awareness of sideeffects than those in an experimental study, and typically report fewer adverse events. The tested sample was not large enough to reliably detect uncommon side-effects and distinguish the immunogenicity of the vaccine in specific patient subgroups. After all, in our study, we only assessed short-term side-effects.

In summary we would like to underline that there were no serious adverse events that warranted a safety concern regarding the use of mRNA COVID-19 vaccines in KTR. These vaccines were welltolerated by KTR, therefore the results of our studies can help patients make the decision to vaccinate and accept repeated doses. 

Covid-19 in elderly kidney transplant recipients

Covid-19 infection in kidney transplant recipients at the epicenter of pandemics

Predictors of humoral response to mrna covid19 vaccines in kidney transplant recipients: A longitudinal study-the covineph project. Vaccines (Basel)

Humoral and cellular immunity to sars-cov-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mrna-1273 or bnt162b2 mrna vaccine

Boosting humoral immunity from mrna covid-19 vaccines in kidney transplant recipients Vaccines (Basel) 2022

A third vaccine dose substantially improves humoral and cellular sars-cov-2 immunity in renal transplant recipients with primary humoral nonresponse

Efficiency of a boost with a third dose of antisars-cov-2 messenger rna-based vaccines in solid organ transplant recipients

A: Three doses of an mrna covid-19 vaccine in solid-organ transplant recipients

Covid-19 vaccination intent, perceptions, and reasons for not vaccinating among groups prioritized for early vaccination -united states

Reactogenicity following receipt of mrna-based covid-19

Safety and cross-variant immunogenicity of a threedose covid-19 mrna vaccine regimen in kidney transplant recipients

Safety and reactogenicity of 2 doses of sars-cov-2 vaccination in solid organ transplant recipients